(Q39489100)

12 September 2017

title

Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer (English)

1 reference

12 September 2017

0 references

prostatic hypertrophy

1 reference

8

A V Schally

1 reference

12 September 2017

2

M Vadillo-Buenfil

1 reference

12 September 2017

5

I Cardenas-Cornejo

1 reference

12 September 2017

D Gonzalez-Barcena

1

1 reference

12 September 2017

F Gomez-Orta

3

1 reference

12 September 2017

M Fuentes Garcia

4

1 reference

12 September 2017

A Graef-Sanchez

6

1 reference

12 September 2017

A M Comaru-Schally

7

1 reference

12 September 2017

publication date

1 January 1994

1 reference

12 September 2017

1 reference

12 September 2017

volume

24

1 reference

12 September 2017

issue

2

1 reference

12 September 2017

page(s)

84-92

1 reference

Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.

12 September 2017

cites work

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Ac-D-NAL(2)1,4FD-Phe2,D-Trp3,D-Arg6-LHRH, a potent antagonist of LHRH, produces transient edema and behavioral changes in rats

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75).

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Effectiveness of ultrasound in the preoperative evaluation of patients with prostatism

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Effect of long-acting gonadotropin-releasing hormone analog (leuprolide) therapy on prostatic size and symptoms in 15 men with benign prostatic hypertrophy

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Suppression of pituitary-gonadal function by a potent new luteinizing hormone-releasing hormone antagonist in normal men

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Comparison of the potential for therapeutic utilities with gonadotropin-releasing hormone agonists and antagonists

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Potent, long-acting luteinizing hormone-releasing hormone antagonists containing new synthetic amino acids: N,N'-dialkyl-D-homoarginines

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release in vitro

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Hormonal effects of single gonadotropin-releasing hormone antagonist doses in men.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Symptom status and quality of life following prostatectomy.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Suppression of gonadotrophin release in many by an inhibitory analogue of L.H.-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Persistent blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Anovulatory effect of a LHRH antagonist in women

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Response to D-Trp-6-LH-RH in advanced adenocarcinoma of pancreas

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.2990240206

Identifiers

DOI

10.1002/PROS.2990240206

1 reference

release_3aww2frqh5dzva2upom4uxibcm

12 September 2017

Fatcat ID

0 references

1 reference